JOHANNESBURG (Reuters) - South Africa's competition watchdog has dropped an investigation into Aspen Pharmacare and Equity Pharmaceutical, saying a case against them for over-charging for cancer medicines "cannot be sustained."
Original Article: South Africa watchdog drops over-charging probe into Aspen, Equity
NEXT ARTICLE